Enlivex Doses First Patient in Phase I Trial
Ticker: ENLV · Form: 6-K · Filed: Apr 3, 2025 · CIK: 1596812
Sentiment: neutral
Topics: clinical-trial, phase-i, drug-development
TL;DR
Enlivex dosed first patient in Phase I trial, watch for efficacy data.
AI Summary
On April 3, 2025, Enlivex Therapeutics Ltd. announced that the first patient has been dosed in an investigator-initiated Phase I trial. This trial will evaluate the safety, tolerability, and initial efficacy of their therapeutic candidate. The company, formerly known as Bioblast Pharma Ltd., is based in Tel Aviv, Israel.
Why It Matters
This marks a significant step in the clinical development of Enlivex's therapeutic candidate, potentially validating its safety and efficacy for future trials and market approval.
Risk Assessment
Risk Level: medium — Phase I trials are early-stage and carry inherent risks regarding safety and efficacy, with a high failure rate for drug candidates.
Key Players & Entities
- Enlivex Therapeutics Ltd. (company) — Registrant
- Bioblast Pharma Ltd. (company) — Former company name
- April 3, 2025 (date) — Date of press release and first patient dosed
FAQ
What is the primary purpose of the Phase I trial announced by Enlivex Therapeutics?
The Phase I trial is designed to evaluate the safety, tolerability, and initial efficacy of Enlivex's therapeutic candidate.
When was the press release regarding the Phase I trial issued?
The press release was issued on April 3, 2025.
What is Enlivex Therapeutics Ltd.'s principal executive office address?
The principal executive offices are located at 14 Einstein Street, Nes Ziona, Israel, 7403618.
What was Enlivex Therapeutics Ltd. formerly known as?
Enlivex Therapeutics Ltd. was formerly known as Bioblast Pharma Ltd. and BIO BLAST PHARMA LTD.
Under which country's laws is Enlivex Therapeutics Ltd. organized?
Enlivex Therapeutics Ltd. is organized under the laws of the State of Israel.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 3, 2025 regarding Enlivex Therapeutics Ltd. (ENLV).